Krsnaa Diagnostics Limited has successfully completed the allotment of unlisted secured redeemable non-convertible debentures worth ₹430 crores to the Asian Development Bank. The Operation Committee of the Board of Directors approved this strategic debt financing transaction on February 23, 2026, marking a significant milestone in the company's fundraising initiatives.

Official Allotment Details

The company has formally disclosed the debenture allotment under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The comprehensive structure demonstrates institutional confidence in the company's growth prospects.

Interest and Redemption Structure

The debentures carry an attractive annual interest rate of 7.790% with a well-structured repayment mechanism designed to balance cash flow management with investor returns.

The redemption will occur through thirteen equal installments, with the repayment schedule commencing six months after the allotment date. This grace period provides Krsnaa Diagnostics with adequate time to deploy the raised capital effectively before beginning the repayment cycle.

Regulatory Compliance and Strategic Partnership

The company has fulfilled all regulatory requirements under SEBI guidelines, with the Operation Committee meeting conducted from 14:30 Hrs to 15:00 Hrs on the allotment date. The Asian Development Bank's participation as the sole investor represents a significant endorsement of Krsnaa Diagnostics' business model and growth strategy within the diagnostics sector.

The debentures are secured by charges created over identified assets of the company as per definitive agreements, providing additional security to the institutional investor. This structured debt instrument reflects competitive pricing for secured debt in the current market environment while providing long-term capital stability for expansion and operational requirements.

Krsnaa Diagnostics Limited's Board of Directors has approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for an extended five-year term. The decision, announced on February 22, 2026, reflects the company's confidence in his leadership and strategic vision for the healthcare diagnostics sector.

Board Decision and Regulatory Compliance

The Board of Directors, acting on recommendations from the Nomination and Remuneration Committee, has accorded approval for Mr. Mutha's re-appointment in accordance with the Companies Act, 2013, SEBI (LODR) Regulations, 2015, and other applicable regulatory provisions. The appointment is subject to shareholder approval through postal ballot.

Leadership Profile and Expertise

Mr. Rajendra Khivraj Mutha brings over two decades of specialized expertise in pharmacy and diagnostics to his executive role. As a certified Pharmacist accredited by the Maharashtra State Pharmacy Council, he leverages extensive industry knowledge to drive the company's strategic vision and operational excellence.

Key Leadership Areas

• Strategic Operations: Spearheads the company's operational excellence initiatives
• Community Health: Leads impactful outreach programs focused on community health, women, and children
• Corporate Social Responsibility: Champions CSR programmes that uplift underserved communities
• Healthcare Innovation: Recognized as a changemaker in Indian healthcare sector

Governance and Independence

The appointment maintains proper corporate governance standards, with Mr. Mutha confirmed as not being related to any other Directors on the company's Board. Additionally, he meets all regulatory compliance requirements and is not debarred from holding directorial positions by SEBI or any other regulatory authority.

Meeting Details and Regulatory Disclosure

The board meeting commenced at 18:30 Hrs. (IST) and concluded at 21:10 Hrs. (IST) on February 22, 2026. The company has filed the necessary disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with both BSE Limited and National Stock Exchange of India Limited.

The re-appointment underscores the board's confidence in Mr. Mutha's ability to continue leading the company's growth trajectory in the competitive healthcare diagnostics market, while maintaining focus on community health initiatives and corporate social responsibility.